We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+23.96%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$283M
AUM Growth
+$33.2M
Cap. Flow
+$6.04M
Cap. Flow %
2.13%
Top 10 Hldgs %
59.75%
Holding
54
New
16
Increased
6
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$46.6M
2
BLU
BELLUS Health Inc.
BLU
+$7.61M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.3M
4
GHRS icon
GH Research
GHRS
+$4.95M
5
KRYS icon
Krystal Biotech
KRYS
+$4.29M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$30.5M
2
EPIX
ESSA Pharma
EPIX
+$6.65M
3
FULC icon
Fulcrum Therapeutics
FULC
+$5.34M
4
APLS
Apellis Pharmaceuticals
APLS
+$4.78M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 93.66%
2 Financials 4.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
26
LeonaBio Inc
LONA
$72.1M
$2.79M 0.98%
29,736
-12,970
-30% -$1.32M
RAIN
27
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$2.73M 0.96%
182,500
+20,255
+12% +$345K
GOSS icon
28
Gossamer Bio
GOSS
$86.9M
$2.7M 0.95%
+215,000
New +$1.98M
MRUS
29
DELISTED
Merus
MRUS
$2.68M 0.95%
+122,000
New +$2.62M
ACRS icon
30
Aclaris Therapeutics
ACRS
$888M
$2.54M 0.89%
140,839
-34,161
-20% -$548K
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$2.49M 0.88%
75,500
-85,000
-53% -$4.78M
AVDL
32
CALL
DELISTED
Avadel Pharmaceuticals
AVDL
$2.45M 0.86%
+250,000
New +$1.97M
VRDN icon
33
Viridian Therapeutics
VRDN
$2.33B
$2.23M 0.79%
+135,807
New +$1.99M
ALLK
34
DELISTED
Allakos
ALLK
$1.85M 0.65%
+17,500
New +$1.56M
RETA
35
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$1.76M 0.62%
17,500
+7,500
+75% +$879K
ALT icon
36
Altimmune
ALT
$589M
$1.7M 0.6%
+150,000
New +$1.82M
BCYC
37
Bicycle Therapeutics
BCYC
$278M
$1.59M 0.56%
+38,184
New +$1.34M
GYRE icon
38
Gyre Therapeutics
GYRE
$695M
$1.5M 0.53%
48,667
-42,666
-47% -$1.4M
RNAM
39
DELISTED
Avidity Biosciences
RNAM
$1.48M 0.52%
60,000
– –
CMRX
40
DELISTED
Chimerix, Inc.
CMRX
$1.3M 0.46%
210,000
-299,164
-59% -$2.06M
CBAY
41
DELISTED
Cymabay Therapeutics
CBAY
$1.1M 0.39%
301,904
– –
CCCC icon
42
C4 Therapeutics
CCCC
$400M
$938K 0.33%
+21,000
New +$899K
ELAN icon
43
Elanco Animal Health
ELAN
$13.1B
$925K 0.33%
+29,000
New +$973K
UTHR icon
44
United Therapeutics
UTHR
$22B
$554K 0.2%
+3,000
New +$591K
NVAX icon
45
Novavax
NVAX
$1.27B
$480K 0.17%
2,315
– –
NUVB.WS
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$242K 0.09%
90,832
– –
ALGS icon
47
Aligos Therapeutics
ALGS
$29.3M
– –
-8,570
Closed -$4.37M
ATXS
48
DELISTED
Astria Therapeutics
ATXS
– –
-195,612
Closed -$2.48M
AVDL
49
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-561,011
Closed -$4.42M
CLDX icon
50
PUT
Celldex Therapeutics
CLDX
$3.22B
– –
-500,000
Closed -$16.7M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return

Acuta Capital Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Acuta Capital Partners held 54 positions worth $283M, up 13% from $250M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners's Q3 2021 filing shows 16 new, 6 increased, 10 reduced and 7 closed positions. Its largest new stake was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M. The largest sale was Celldex Therapeutics, an estimated $30.5M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 87% a quarter earlier, followed by Financials.

  • Acuta Capital Partners's largest Q3 2021 buy was Whitehawk Therapeutics: 1,529,402 shares worth $44.9M.
  • Acuta Capital Partners added most to Iovance Biotherapeutics in Q3 2021, an estimated $5.3M increase.
  • Acuta Capital Partners's biggest Q3 2021 reduction was Celldex Therapeutics, cutting an estimated $30.5M.
  • Acuta Capital Partners fully exited ESSA Pharma in Q3 2021, selling an estimated $6.65M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $283M portfolio in Q3 2021.
  • Acuta Capital Partners opened 16 new positions and closed 7 in Q3 2021.
  • Acuta Capital Partners's portfolio value rose 13% quarter-over-quarter to $283M.

Based on Acuta Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.